Cargando…

Current progress and future perspectives of neoadjuvant anti-PD-1/PD-L1 therapy for colorectal cancer

Immunotherapies, especially the programmed cell death 1/programmed cell death ligand 1 (PD-1/PD-L1) inhibitors, have revolutionized the therapeutic strategies of various cancers. As for colorectal cancer (CRC), the current clinical application of PD-1/PD-L1 inhibitors are mainly used according to th...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Zhengyang, Wu, Guocong, Zhang, Xiao, Gao, Jiale, Meng, Cong, Liu, Yishan, Wei, Qi, Sun, Liting, Wei, Pengyu, Bai, Zhigang, Yao, Hongwei, Zhang, Zhongtao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9501688/
https://www.ncbi.nlm.nih.gov/pubmed/36159842
http://dx.doi.org/10.3389/fimmu.2022.1001444
_version_ 1784795535145697280
author Yang, Zhengyang
Wu, Guocong
Zhang, Xiao
Gao, Jiale
Meng, Cong
Liu, Yishan
Wei, Qi
Sun, Liting
Wei, Pengyu
Bai, Zhigang
Yao, Hongwei
Zhang, Zhongtao
author_facet Yang, Zhengyang
Wu, Guocong
Zhang, Xiao
Gao, Jiale
Meng, Cong
Liu, Yishan
Wei, Qi
Sun, Liting
Wei, Pengyu
Bai, Zhigang
Yao, Hongwei
Zhang, Zhongtao
author_sort Yang, Zhengyang
collection PubMed
description Immunotherapies, especially the programmed cell death 1/programmed cell death ligand 1 (PD-1/PD-L1) inhibitors, have revolutionized the therapeutic strategies of various cancers. As for colorectal cancer (CRC), the current clinical application of PD-1/PD-L1 inhibitors are mainly used according to the mutation pattern, which is categorized into deficient mismatch repair (dMMR)/high levels of microsatellite instability (MSI-H) and proficient mismatch repair (pMMR), or non-high levels of microsatellite instability (non-MSI-H). PD-1/PD-L1 inhibitors have been proven to have favorable outcomes against dMMR/MSI-H CRC because of more T-cell infiltration into tumor tissues. Nevertheless, the effectiveness of PD-1/PD-L1 inhibitors in pMMR/non-MSI-H CRC is still uncertain. Because of the quite-lower proportion of dMMR/MSI-H in CRC, PD-1/PD-L1 inhibitors have been reported to combine with other antitumor treatments including chemotherapy, radiotherapy, and targeted therapy for better therapeutic effect in recent clinical trials. Neoadjuvant therapy, mainly including chemotherapy and radiotherapy, not only can reduce clinical stage but also benefit from local control, which can improve clinical symptoms and the quality of life. Adding immunotherapy into neoadjuvant therapy may change the treatment strategy of primary resectable or some metastatic CRC. In this review, we focus on the development of neoadjuvant anti-PD-1/PD-L1 therapy and discuss the future perspectives in CRC.
format Online
Article
Text
id pubmed-9501688
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-95016882022-09-24 Current progress and future perspectives of neoadjuvant anti-PD-1/PD-L1 therapy for colorectal cancer Yang, Zhengyang Wu, Guocong Zhang, Xiao Gao, Jiale Meng, Cong Liu, Yishan Wei, Qi Sun, Liting Wei, Pengyu Bai, Zhigang Yao, Hongwei Zhang, Zhongtao Front Immunol Immunology Immunotherapies, especially the programmed cell death 1/programmed cell death ligand 1 (PD-1/PD-L1) inhibitors, have revolutionized the therapeutic strategies of various cancers. As for colorectal cancer (CRC), the current clinical application of PD-1/PD-L1 inhibitors are mainly used according to the mutation pattern, which is categorized into deficient mismatch repair (dMMR)/high levels of microsatellite instability (MSI-H) and proficient mismatch repair (pMMR), or non-high levels of microsatellite instability (non-MSI-H). PD-1/PD-L1 inhibitors have been proven to have favorable outcomes against dMMR/MSI-H CRC because of more T-cell infiltration into tumor tissues. Nevertheless, the effectiveness of PD-1/PD-L1 inhibitors in pMMR/non-MSI-H CRC is still uncertain. Because of the quite-lower proportion of dMMR/MSI-H in CRC, PD-1/PD-L1 inhibitors have been reported to combine with other antitumor treatments including chemotherapy, radiotherapy, and targeted therapy for better therapeutic effect in recent clinical trials. Neoadjuvant therapy, mainly including chemotherapy and radiotherapy, not only can reduce clinical stage but also benefit from local control, which can improve clinical symptoms and the quality of life. Adding immunotherapy into neoadjuvant therapy may change the treatment strategy of primary resectable or some metastatic CRC. In this review, we focus on the development of neoadjuvant anti-PD-1/PD-L1 therapy and discuss the future perspectives in CRC. Frontiers Media S.A. 2022-09-09 /pmc/articles/PMC9501688/ /pubmed/36159842 http://dx.doi.org/10.3389/fimmu.2022.1001444 Text en Copyright © 2022 Yang, Wu, Zhang, Gao, Meng, Liu, Wei, Sun, Wei, Bai, Yao and Zhang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Yang, Zhengyang
Wu, Guocong
Zhang, Xiao
Gao, Jiale
Meng, Cong
Liu, Yishan
Wei, Qi
Sun, Liting
Wei, Pengyu
Bai, Zhigang
Yao, Hongwei
Zhang, Zhongtao
Current progress and future perspectives of neoadjuvant anti-PD-1/PD-L1 therapy for colorectal cancer
title Current progress and future perspectives of neoadjuvant anti-PD-1/PD-L1 therapy for colorectal cancer
title_full Current progress and future perspectives of neoadjuvant anti-PD-1/PD-L1 therapy for colorectal cancer
title_fullStr Current progress and future perspectives of neoadjuvant anti-PD-1/PD-L1 therapy for colorectal cancer
title_full_unstemmed Current progress and future perspectives of neoadjuvant anti-PD-1/PD-L1 therapy for colorectal cancer
title_short Current progress and future perspectives of neoadjuvant anti-PD-1/PD-L1 therapy for colorectal cancer
title_sort current progress and future perspectives of neoadjuvant anti-pd-1/pd-l1 therapy for colorectal cancer
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9501688/
https://www.ncbi.nlm.nih.gov/pubmed/36159842
http://dx.doi.org/10.3389/fimmu.2022.1001444
work_keys_str_mv AT yangzhengyang currentprogressandfutureperspectivesofneoadjuvantantipd1pdl1therapyforcolorectalcancer
AT wuguocong currentprogressandfutureperspectivesofneoadjuvantantipd1pdl1therapyforcolorectalcancer
AT zhangxiao currentprogressandfutureperspectivesofneoadjuvantantipd1pdl1therapyforcolorectalcancer
AT gaojiale currentprogressandfutureperspectivesofneoadjuvantantipd1pdl1therapyforcolorectalcancer
AT mengcong currentprogressandfutureperspectivesofneoadjuvantantipd1pdl1therapyforcolorectalcancer
AT liuyishan currentprogressandfutureperspectivesofneoadjuvantantipd1pdl1therapyforcolorectalcancer
AT weiqi currentprogressandfutureperspectivesofneoadjuvantantipd1pdl1therapyforcolorectalcancer
AT sunliting currentprogressandfutureperspectivesofneoadjuvantantipd1pdl1therapyforcolorectalcancer
AT weipengyu currentprogressandfutureperspectivesofneoadjuvantantipd1pdl1therapyforcolorectalcancer
AT baizhigang currentprogressandfutureperspectivesofneoadjuvantantipd1pdl1therapyforcolorectalcancer
AT yaohongwei currentprogressandfutureperspectivesofneoadjuvantantipd1pdl1therapyforcolorectalcancer
AT zhangzhongtao currentprogressandfutureperspectivesofneoadjuvantantipd1pdl1therapyforcolorectalcancer